ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
인간화 항체 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 357억 달러에서 2025년에는 397억 달러로, CAGR 13.2%로 성장하였습니다. 지난 수년간의 성장은 표적 요법에 대한 수요 증가, 만성 질환의 유병률 상승, 단일클론항체의 채용 확대, 바이오시밀러 시장의 확대, 의료비 지출 증가에 의해 발생하였습니다.
인간화 항체 시장 규모는 향후 수년간 급속한 성장이 예상됩니다. 2029년에는 643억 3,000만 달러에 달하고, CAGR은 12.8%를 나타낼 전망입니다. 예측기간의 성장은 암 발생률의 상승, 자가면역질환의 유병률 증가, 맞춤 의료에 대한 수요 증가, 바이오시밀러 시장의 확대, 의료비 지출 증가에 의해 발생할 전망입니다. 예측 기간의 주요 동향에는 인공지능(AI)과 머신러닝을 활용한 항체 발견, 저온 전자 현미경(크라이오 전자 현미경)을 이용한 구조 결정, 차세대 시퀀싱 기술을 이용한 레퍼토리 분석, 표적 검증용 단일 세포 리보 핵산(RNA) 시퀀싱, 최적화된 링커와 페이로드를 갖는 항체 약제 복합체(ADC) 등이 있습니다.
감염증의 확대는 향후 수년간 인간화 항체 시장의 성장을 가속할 것으로 예측됩니다. 감염은 박테리아, 바이러스, 곰팡이, 기생충과 같은 병원성 미생물에 의해 유발되는 질병으로, 개인 간에 직접 또는 간접적으로 전파될 수 있습니다. 여행 증가로 인해 병원체의 경계 확산이 가속화되어 감염증 발생률이 상승세에 있습니다. 인간화 항체는 표적화된 면역 반응을 제공함으로써 감염 치료를 지원하고 특정 병원체의 퇴치에 적합합니다. 천연 인간 항체와 매우 유사하므로 면역 거부 위험을 줄이고 치료의 안전성과 치료 효과를 향상시킵니다. 예를 들어, 영국 정부 기관인 영국 보건안보청(UK Health Security Agency)에 따르면 2024년 2월 영국의 결핵 사례 수는 2023년 4,850건에 이르렀으며 2022년 4,380건에서 10.7% 증가했습니다. 이와 같이 감염증의 확대가 인간화 항체 시장의 성장을 견인하고 있습니다.
인간화 항체 시장의 주요 기업은 적응증의 확대와 보다 강력하고 지속적인 항종양 활성화 제공을 목적으로 인간화 이중특이적 항체 등의 혁신적인 제품을 개발하고 있습니다. 인간화 이중특이적 항체는 2개의 상이한 항원 또는 동일한 항원 상의 2개의 상이한 에피토프에 동시에 결합하도록 설계되는 동시에 천연 인간 항체와 매우 유사하도록 변형되었습니다. 예를 들어, 2024년 11월 20일, 아일랜드에 본사를 둔 바이오 의약품 기업인 재즈 파마슈티컬스사는 이미 치료 이력이 있는 절제 불능 또는 전이성 HER2 양성(IHC 3) 담도암에 대한 Ziihera(자니다타맙-hrii)에 대해 미국 식품 의약국(FDA)의 승인을 취득했습니다. 본 제품은 인간화 면역글로불린 G(IgG) 이중특이적 항체이며, 인간 상피 성장 인자 수용체 2(HER2)의 2개의 세포외부위를 표적으로 합니다. 독자적인 작용기전에 의해 면역 이펙터 세포를 동원해, 암 세포에 직접 세포자살을 유도하므로 사전 면역 활성화를 필요로 하지 않고 악성 세포를 표적으로 한 공격을 가능하게 합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 인간화 항체 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 인간화 항체 시장 : 성장률 분석
세계의 인간화 항체 시장 실적 : 규모와 성장(2019-2024년)
세계의 인간화 항체 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 인간화 항체 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 인간화 항체 시장 : 항체 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
인간화 항체
키메라 항체
완전 인간화 항체
마우스 항체
세계의 인간화 항체 시장 : 제품 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일클론항체
다중클론항체
항체 약제 복합체
세계의 인간화 항체 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
암
자가면역질환
감염증
심혈관 질환
기타
세계의 인간화 항체 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
연구기관
진단 실험실
기타
세계의 인간화 항체 시장 : 인간화 항체별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일특이적 치료용 항체
이중특이적 및 다중특이적 항체
항체 약제 복합체
단일 사슬 가변 도메인 단편 항체
단편 항원 결합 항체
세계의 인간화 항체 시장 : 키메라 항체별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일특이적 치료용 항체
이중특이적 및 다중특이적 항체
항체 약제 복합체
단일 사슬 가변 도메인 단편 기반 항체
단편 항원 결합 기반 항체
세계의 인간화 항체 시장 : 완전 인간화 항체별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일특이적 치료용 항체
이중특이적과 다중특이적 항체
항체 약제 복합체
단일 사슬 가변 도메인 단편 기반 항체
반감기 연장형 항체
세계의 인간화 항체 시장 : 마우스 항체별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일특이적 연구용 항체
하이브리도마 유래 항체
항체 약물 복합체 전구체
단일 사슬 가변 도메인 단편 기반 항체
단편 항원 결합 기반 항체
제7장 지역별 및 국가별 분석
세계의 인간화 항체 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 인간화 항체 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
인간화 항체 시장 : 경쟁 구도
인간화 항체 시장 : 기업 프로파일
Johnson & Johnson
Roche Holding AG
Merck & Co. Inc.
Pfizer Inc.
AbbVie Inc.
제31장 기타 주요 기업 및 혁신 기업
Sanofi SA
Novartis AG
AstraZeneca PLC
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Eli Lilly and Company
Takeda Pharmaceutical Company Limited
Amgen Inc.
Biogen Inc.
Daiichi Sankyo Company Limited
UCB SA
Genmab A/S
Xencor Inc.
Zymeworks Inc.
MacroGenics Inc.
제32장 세계 시장의 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 전략
인간화 항체 시장(2029년) : 새로운 기회를 제공하는 국가
인간화 항체 시장(2029년) : 새로운 기회를 제공하는 부문
인간화 항체 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
Humanized antibody is a type of monoclonal antibody engineered to closely mimic human antibodies while maintaining the antigen binding specificity of the original non human antibody. It is produced by replacing most of the non human antibody's protein sequences with corresponding human sequences, reducing the risk of immune reactions. It is widely used in research and therapy to target specific molecules with high precision and lower immunogenicity.
The main antibody types of humanized antibodies include humanized antibodies, chimeric antibodies, fully human antibodies, and murine antibodies. Humanized antibodies are laboratory engineered antibodies originally derived from non human species in which most of the molecular structure is replaced with human antibody components while retaining only the antigen binding regions necessary for target recognition. The various product types include monoclonal antibodies, polyclonal antibodies, and antibody drug conjugates, and they are applied in cancer, autoimmune diseases, infectious diseases, cardiovascular diseases, and others, serving end users such as hospitals, research institutes, diagnostic laboratories, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The humanized antibody market research report is one of a series of new reports from The Business Research Company that provides humanized antibody market statistics, including humanized antibody industry global market size, regional shares, competitors with a humanized antibody market share, detailed humanized antibody market segments, market trends and opportunities, and any further data you may need to thrive in the humanized antibody industry. This humanized antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The humanized antibody market size has grown rapidly in recent years. It will grow from $35.70 billion in 2024 to $39.70 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to rising demand for targeted therapies, increasing prevalence of chronic diseases, growing adoption of monoclonal antibodies, expansion of the biosimilar market, and rising healthcare expenditure.
The humanized antibody market size is expected to see rapid growth in the next few years. It will grow to $64.33 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to rising incidence of cancer, increasing prevalence of autoimmune diseases, growing demand for personalized medicine, expansion of the biosimilar market, and rising healthcare expenditure. Major trends in the forecast period include artificial intelligence and machine learning driven antibody discovery, cryo-electron microscopy enabled structure determination, next generation sequencing powered repertoire mining, single cell ribonucleic acid sequencing for target validation, and antibody drug conjugates with optimized linkers and payloads.
The growing prevalence of infectious diseases is expected to drive the growth of the humanized antibody market in the coming years. Infectious diseases are illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, or parasites, which can be transmitted directly or indirectly between individuals. The incidence of infectious diseases is rising due to increased travel, which accelerates the spread of pathogens across borders. Humanized antibodies support infectious disease treatment by providing targeted immune responses, making them suitable for combating specific pathogens. They reduce the risk of immune rejection by closely resembling natural human antibodies, improving treatment safety and therapeutic effectiveness. For example, in February 2024, according to the UK Health Security Agency, a UK based government agency, tuberculosis cases in England rose to 4,850 in 2023, an increase of 10.7 percent from 4,380 cases in 2022. Therefore, the rising prevalence of infectious diseases is driving the expansion of the humanized antibody market.
Major companies in the humanized antibody market are developing innovative products such as humanized bispecific antibodies to expand labelable indications and provide stronger, more durable antitumor activity. Humanized bispecific antibodies are engineered to bind simultaneously to two different antigens or two distinct epitopes on the same antigen while being modified to closely resemble natural human antibodies. For example, on November 20, 2024, Jazz Pharmaceuticals plc, an Ireland based biopharmaceutical company, received accelerated approval from the U.S. Food and Drug Administration for Ziihera (zanidatamab-hrii) for previously treated, unresectable, or metastatic HER2-positive (IHC 3+) biliary tract cancer. It is a humanized, immunoglobulin G bispecific antibody targeting human epidermal growth factor receptor 2 (HER2) at two extracellular sites. It incorporates a proprietary mechanism that engages immune effector cells and directly induces apoptosis in cancer cells, enabling a targeted attack on malignant cells without prior immune activation.
In September 2024, Valerio Therapeutics S.A., a France based clinical-stage biotechnology company, acquired Emglev Therapeutics for an undisclosed amount. Through this acquisition, Valerio Therapeutics aims to strengthen its antibody discovery capabilities by integrating Emglev's humanized single-domain antibody (sdAb) technology to accelerate the development of next-generation therapeutic candidates across multiple disease areas. Emglev Therapeutics is a France based biotechnology company specializing in humanized single-domain antibody development.
Major companies operating in the humanized antibody market are Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Genmab A/S, Xencor Inc., Zymeworks Inc., MacroGenics Inc.
North America was the largest region in the humanized antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in humanized antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the humanized antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The humanized antibody market consists of sales of humanized bispecific antibodies, humanized antibody fragments, humanized antibody libraries, and antibody humanization kits and reagents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Humanized Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on humanized antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for humanized antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The humanized antibody market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Antibody Type: Humanized Antibodies; Chimeric Antibodies; Fully Human Antibodies; Murine Antibodies
2) By Product Type: Monoclonal Antibodies; Polyclonal Antibodies; Antibody-Drug Conjugates
3) By Application: Cancer; Autoimmune Diseases; Infectious Diseases; Cardiovascular Diseases; Other Applications
4) By End-User: Hospitals; Research Institutes; Diagnostic Laboratories; Other End-Users
Subsegments:
1) By Humanized Antibodies: Monospecific Therapeutic Antibodies; Bispecific And Multispecific Antibodies; Antibody Drug Conjugates; Single Chain Variable Fragment Based Antibodies; Fragment Antigen Binding Based Antibodies
2) By Chimeric Antibodies: Monospecific Therapeutic Antibodies; Bispecific And Multispecific Antibodies; Antibody Drug Conjugates; Single Chain Variable Fragment Based Antibodies; Fragment Antigen Binding Based Antibodies
3) By Fully Human Antibodies: Monospecific Therapeutic Antibodies; Bispecific And Multispecific Antibodies; Antibody Drug Conjugates; Single Chain Variable Fragment Based Antibodies; Long Acting Half Life Extended Antibodies
4) By Murine Antibodies: Monospecific Research Grade Antibodies; Hybridoma Derived Antibodies; Antibody Drug Conjugate Precursors; Single Chain Variable Fragment Based Antibodies; Fragment Antigen Binding Based Antibodies
Companies Mentioned: Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; Pfizer Inc.; AbbVie Inc.; Sanofi S.A.; Novartis AG; AstraZeneca PLC; Bristol-Myers Squibb Company; GlaxoSmithKline plc; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Amgen Inc.; Biogen Inc.; Daiichi Sankyo Company Limited; UCB S.A.; Genmab A/S; Xencor Inc.; Zymeworks Inc.; MacroGenics Inc.
Countries:
Table of Contents
1. Executive Summary
2. Humanized Antibody Market Characteristics
3. Humanized Antibody Market Trends And Strategies
4. Humanized Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Humanized Antibody Growth Analysis And Strategic Analysis Framework
5.1. Global Humanized Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Humanized Antibody Market Growth Rate Analysis
5.4. Global Humanized Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Humanized Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Humanized Antibody Total Addressable Market (TAM)
6. Humanized Antibody Market Segmentation
6.1. Global Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Humanized Antibodies
Chimeric Antibodies
Fully Human Antibodies
Murine Antibodies
6.2. Global Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Polyclonal Antibodies
Antibody-Drug Conjugates
6.3. Global Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer
Autoimmune Diseases
Infectious Diseases
Cardiovascular Diseases
Other Applications
6.4. Global Humanized Antibody Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Research Institutes
Diagnostic Laboratories
Other End-Users
6.5. Global Humanized Antibody Market, Sub-Segmentation Of Humanized Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monospecific Therapeutic Antibodies
Bispecific And Multispecific Antibodies
Antibody Drug Conjugates
Single Chain Variable Fragment Based Antibodies
Fragment Antigen Binding Based Antibodies
6.6. Global Humanized Antibody Market, Sub-Segmentation Of Chimeric Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monospecific Therapeutic Antibodies
Bispecific And Multispecific Antibodies
Antibody Drug Conjugates
Single Chain Variable Fragment Based Antibodies
Fragment Antigen Binding Based Antibodies
6.7. Global Humanized Antibody Market, Sub-Segmentation Of Fully Human Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monospecific Therapeutic Antibodies
Bispecific And Multispecific Antibodies
Antibody Drug Conjugates
Single Chain Variable Fragment Based Antibodies
Long Acting Half Life Extended Antibodies
6.8. Global Humanized Antibody Market, Sub-Segmentation Of Murine Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monospecific Research Grade Antibodies
Hybridoma Derived Antibodies
Antibody Drug Conjugate Precursors
Single Chain Variable Fragment Based Antibodies
Fragment Antigen Binding Based Antibodies
7. Humanized Antibody Market Regional And Country Analysis
7.1. Global Humanized Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Humanized Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
